



ASX Release  
1 July 2021

ASX Code: MEM

### **Felix Device Verification Passed**

Australian-based bio-separations company Memphasys Limited (ASX: MEM) (“Memphasys” or “the Company”) is pleased to advise that all remaining verification tasks associated with the upgraded Felix Device have successfully passed the verification process.

A number of validation tasks remain outstanding; however, they are expected to be completed as previously advised during the quarter ending 30 September 2021.

Prior to completion of the validation tasks Memphasys will provide the upgraded Felix Device to its Key Opinion Leader (KOL) network for in-clinic testing. The Company has placed a priority for testing on the KOL locations in its identified early commercial markets (i.e. Japan, India, Canada and New Zealand)

Once clinical testing of the upgraded Felix device has been completed successfully, sales discussions with KOL partners and other prospects in early access markets will resume. The Company anticipates initiating commercial sales discussions in early access markets in the latter part of the quarter ending 30 September 2021.

**This announcement has been approved for release by the board of Memphasys Limited.**

**ENDS**

For further information please contact:

Alison Coutts  
Executive Chairman  
Memphasys Limited  
T: +61 2 8415 7300  
E: [alison.coutts@memphasys.com](mailto:alison.coutts@memphasys.com)

David Tasker  
Managing Director  
Chapter One Advisors Limited  
T: +0433 112 936  
E: [dtasker@chapteroneadvisors.com.au](mailto:dtasker@chapteroneadvisors.com.au)

### **About Memphasys**

Memphasys Limited is focused on reproductive biotechnology and proprietary cell separation techniques. It is developing novel medical devices, diagnostics, and media with application to assisted reproduction technologies, including IVF in humans and artificial insemination in animals.

Website: [www.memphasys.com.au](http://www.memphasys.com.au)

For personal use only